Clinical outcomes are complex and often multi-systemic. Early identification and standardization are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical outcomes, imaging checks, laboratory tests and pathological biopsies.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of stem cell, monocytes, B and NK lymphocyte reduction treatments require individualized development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up, and multi-dimensional management. In recent years, with the development of therapeutic-focused, immune-regulatory treatments and precision medicine, significant improvements have been made in many previously difficult-to-treat blood tumour diseases.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted in the course of treatment. Multidisciplinary collaboration (MDT) is especially important for integrated management of stem cell, monocytes, and BNK lymphocytes reduction. The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of blood oncology, to provide the following services to patients: 1.
Remote pre-diagnosis: pre-examination of medical history, precise diagnostic directions and medical advice by a team of experts; 2. Interviews in China: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3. Full-service: providing one-stop services: providing medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.